CA2412188A1 - Derives 3-azabicyclo¬3.1.0| hexane utile en therapie - Google Patents

Derives 3-azabicyclo¬3.1.0| hexane utile en therapie Download PDF

Info

Publication number
CA2412188A1
CA2412188A1 CA002412188A CA2412188A CA2412188A1 CA 2412188 A1 CA2412188 A1 CA 2412188A1 CA 002412188 A CA002412188 A CA 002412188A CA 2412188 A CA2412188 A CA 2412188A CA 2412188 A1 CA2412188 A1 CA 2412188A1
Authority
CA
Canada
Prior art keywords
alkyl
optionally substituted
aryl
halogen
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002412188A
Other languages
English (en)
Inventor
Bernard Joseph Banks
David Morris Gethin
Ashley Edward Fenwick
Douglas James Critcher
Graham Lunn
Stephen Paul Gibson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2412188A1 publication Critical patent/CA2412188A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne des composés de la formule I, dans laquelle les substituants sont tels que définis dans le descriptif, et les dérivés ou promédicaments, acceptables au plan pharmaceutique ou vétérinaire, sont utiles au plan pharmaceutique ou vétérinaire, car ils se lient en particulier à des récepteurs opioïdes (par exemple les récepteurs opioïdes µ, .kappa. et .delta.). On peut probablement les utiliser dans le traitement de maladies ou de conditions modulées par des récepteurs opioïdes, par exemple: syndrome du côlon irritable; constipation; nausée; vomissement; dermatoses prurigineuses, telles que la dermatite allergique et l'atopie; troubles de l'alimentation; surdoses opiacées; dépression; accoutumance au tabac et à l'alcool; dysfonctionnement sexuel; état de choc; accident vasculaire cérébral; lésions de la moelle épinière et traumatisme crânien.
CA002412188A 2000-06-23 2001-06-07 Derives 3-azabicyclo¬3.1.0| hexane utile en therapie Abandoned CA2412188A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0015562.2A GB0015562D0 (en) 2000-06-23 2000-06-23 Heterocycles
GB0015562.2 2000-06-23
PCT/IB2001/001035 WO2001098267A1 (fr) 2000-06-23 2001-06-07 Derives 3-azabicyclo[3.1.0] hexane ayant une affinite pour le recepteur opioide

Publications (1)

Publication Number Publication Date
CA2412188A1 true CA2412188A1 (fr) 2001-12-27

Family

ID=9894368

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002412188A Abandoned CA2412188A1 (fr) 2000-06-23 2001-06-07 Derives 3-azabicyclo¬3.1.0| hexane utile en therapie

Country Status (34)

Country Link
EP (1) EP1292574A1 (fr)
JP (1) JP2004512263A (fr)
KR (1) KR20040002386A (fr)
CN (1) CN1639121A (fr)
AP (1) AP2002002698A0 (fr)
AR (1) AR028969A1 (fr)
AU (1) AU781837B2 (fr)
BG (1) BG107329A (fr)
BR (1) BR0111867A (fr)
CA (1) CA2412188A1 (fr)
CZ (1) CZ20023967A3 (fr)
DO (1) DOP2001000187A (fr)
DZ (1) DZ3368A1 (fr)
EA (1) EA005117B1 (fr)
GB (1) GB0015562D0 (fr)
HR (1) HRP20020998A2 (fr)
HU (1) HUP0301228A3 (fr)
IL (1) IL153427A0 (fr)
IS (1) IS6637A (fr)
MA (1) MA26915A1 (fr)
MX (1) MXPA02012878A (fr)
NO (1) NO20026168L (fr)
NZ (1) NZ523141A (fr)
OA (1) OA12293A (fr)
PA (1) PA8519401A1 (fr)
PE (1) PE20020253A1 (fr)
PL (1) PL365956A1 (fr)
SK (1) SK17172002A3 (fr)
TN (1) TNSN01094A1 (fr)
UA (1) UA73176C2 (fr)
UY (1) UY26787A1 (fr)
WO (1) WO2001098267A1 (fr)
YU (1) YU91802A (fr)
ZA (1) ZA200210278B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2463264C (fr) * 2001-10-22 2009-05-26 Pfizer Products Inc. Derives 3-azabicyclo (3.1.0) hexane en tant qu'antagonistes de recepteur opioide
CN100411618C (zh) * 2002-05-17 2008-08-20 迪欧加药品公司 有效的选择性阿片受体调制剂化合物的用途
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
US7855298B2 (en) 2004-02-23 2010-12-21 Glaxo Group Limited Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine D3 receptors
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
DE602006017543D1 (de) 2005-06-14 2010-11-25 Glaxo Group Ltd Neue verbindungen
ATE498619T1 (de) * 2006-04-03 2011-03-15 Glaxo Group Ltd Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
CN101677997B (zh) 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
ES2645725T3 (es) 2010-06-11 2017-12-07 Rhodes Technologies Procesos catalizados por metales de transición para la preparación de compuestos de N-alilo y uso de los mismos
BR112013007566A2 (pt) 2010-09-28 2016-08-02 Panacea Biotec Ltd novos compostos bicíclicos
DK3072884T3 (da) * 2013-11-20 2020-03-09 Sanwa Kagaku Kenkyusho Co 3-azabicyclo[3.1.0]hexanderivat og anvendelse deraf til medicinske formål
EP3299357A4 (fr) 2015-05-20 2018-11-14 Sanwa Kagaku Kenkyusho Co., Ltd. Cristal de sel de nouveau dérivé de 3-azabicyclo[3.1.0]hexane et son utilisation pharmaceutique
AU2018221148B2 (en) * 2017-02-17 2022-05-05 Trevena, Inc. 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
BR112019016775A2 (pt) 2017-02-17 2020-03-31 Trevena, Inc. Compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 7 membros, métodos de uso e produção dos mesmos
US20200237720A1 (en) 2017-03-02 2020-07-30 Sanwa Kagaku Kenkyusho Co., Ltd. Therapeutic agent for alcohol use disorders
CN108250088B (zh) * 2018-01-04 2020-10-30 四川之江高新材料股份有限公司 N，n，n′-三甲基-n′-羟乙基双氨基乙基醚的制备方法
CN115825305B (zh) * 2022-10-21 2024-09-20 昆明理工大学 一种分子印迹固相微萃取纤维及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065230A (en) * 1959-03-16 1962-11-20 Burroughs Wellcome Co Azabicyclohexanes and method of preparing them
NZ224236A (en) * 1987-04-16 1990-08-28 Lilly Co Eli Trans 3,4 pyridine derivatives and pharmaceutical compositions
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
DE4341403A1 (de) * 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5

Also Published As

Publication number Publication date
HUP0301228A2 (hu) 2003-08-28
WO2001098267A8 (fr) 2003-02-27
BG107329A (en) 2003-07-31
CZ20023967A3 (cs) 2004-02-18
WO2001098267A1 (fr) 2001-12-27
AU6259101A (en) 2002-01-02
CN1639121A (zh) 2005-07-13
NO20026168D0 (no) 2002-12-20
DZ3368A1 (fr) 2001-12-27
UY26787A1 (es) 2002-01-31
KR20040002386A (ko) 2004-01-07
OA12293A (en) 2004-03-18
MA26915A1 (fr) 2004-12-20
PE20020253A1 (es) 2002-04-08
PL365956A1 (en) 2005-01-24
TNSN01094A1 (fr) 2005-11-10
AR028969A1 (es) 2003-05-28
EP1292574A1 (fr) 2003-03-19
ZA200210278B (en) 2003-12-19
JP2004512263A (ja) 2004-04-22
MXPA02012878A (es) 2003-05-14
YU91802A (sh) 2006-05-25
AU781837B2 (en) 2005-06-16
UA73176C2 (en) 2005-06-15
NZ523141A (en) 2005-06-24
IS6637A (is) 2002-11-28
NO20026168L (no) 2003-02-18
GB0015562D0 (en) 2000-08-16
HUP0301228A3 (en) 2005-08-29
HRP20020998A2 (en) 2004-02-29
IL153427A0 (en) 2003-07-06
PA8519401A1 (es) 2002-12-30
AP2002002698A0 (en) 2002-12-31
EA005117B1 (ru) 2004-10-28
DOP2001000187A (es) 2002-03-30
SK17172002A3 (sk) 2004-09-08
EA200201269A1 (ru) 2003-06-26
BR0111867A (pt) 2003-07-01

Similar Documents

Publication Publication Date Title
CA2356300C (fr) Derives 3-azabicyclo[3.1.0]hexane utiles en therapie
CA2412188A1 (fr) Derives 3-azabicyclo¬3.1.0| hexane utile en therapie
US5834493A (en) Indole derivatives as 5-HT1A and/or 5-HT2 ligands
CN110997661A (zh) 环丙基脲甲酰肽2受体和甲酰肽1受体激动剂
FR2861074A1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
JP2003034689A (ja) ４−複素環式環縮合アリールピペリジン誘導体
WO2004013100A2 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
OA10863A (en) 3-Azetidinylalkylpiperidines or-pyrrolidines as tachykinin antagonists
US20020025948A1 (en) 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
CA2794176A1 (fr) Nouveaux derives de benzamide
JP3752130B2 (ja) 掻痒治療用新規４−アリールピペリジン誘導体
US20030207876A1 (en) 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy
JP2006525320A (ja) Ｃｏｘ阻害剤
KR100504647B1 (ko) 오피에이트 수용체 리간드로서의 3-아자비시클로[3.1.0.]헥산 유도체
JP2011500590A (ja) ケモカイン受容体のモジュレータとしてのピペリジニルヒドロキシエチルピペリジン誘導体
MXPA01006528A (en) 3-azabicyclo[3.1.0.]hexane derivatives as opiate receptors ligands
CA2751863A1 (fr) Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl]-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique
MXPA01005034A (en) Pyrrolidine derivatives-ccr-3 receptor antagonists

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued